Get started
Keyword

FOLFIRI

Description: A chemotherapy regimen combining folinic acid, fluorouracil, and irinotecan, commonly used to treat colorectal cancer.
Wikidata ID: wiki/Q1389369
OpenAlex ID: keywords/folfiri
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 · Eric Van Cutsem, Claus-Henning Köhne, et al. · New England Journal of Medicine · 3,879
PDF
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 · Christophe Tournigand, Thierry André, et al. · Journal of Clinical Oncology · 2,916
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
2011 · Eric Van Cutsem, Claus-Henning Köhne, et al. · Journal of Clinical Oncology · 1,889
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
2014 · Volker Heinemann, Ludwig Fischer von Weikersthal, et al. · The Lancet Oncology · 1,745
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
2019 · Scott Kopetz, Axel Grothey, et al. · New England Journal of Medicine · 1,482
PDF
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
2012 · Eric Van Cutsem, Josep Tabernero, et al. · Journal of Clinical Oncology · 1,402
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
2007 · Alfredo Falcone, Sergio Ricci, et al. · Journal of Clinical Oncology · 1,243
PDF
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
2015 · Chiara Cremolini, Fotios Loupakis, et al. · The Lancet Oncology · 1,087
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
2014 · Fotios Loupakis, Chiara Cremolini, et al. · New England Journal of Medicine · 1,063
PDF
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
2010 · Marc Peeters, Timothy Jay Price, et al. · Journal of Clinical Oncology · 1,007
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
2009 · Gunnar Folprecht, Thomas Gruenberger, et al. · The Lancet Oncology · 963
A colorectal cancer classification system that associates cellular phenotype and responses to therapy
2013 · Anguraj Sadanandam, Costas A Lyssiotis, et al. · Nature Medicine · 961
PDF
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
2015 · Josep Tabernero, Takayuki Yoshino, et al. · The Lancet Oncology · 952
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
2022 · Luis A Diaz, Kai-Keen Shiu, et al. · The Lancet Oncology · 949
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
2017 · Alan P. Venook, Donna Niedzwiecki, et al. · JAMA · 899
PDF
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study
2007 · Charles S. Fuchs, John Marshall, et al. · Journal of Clinical Oncology · 851
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
2015 · Eric Van Cutsem, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 790
PDF
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale
2005 · Giuseppe Colucci, Vittorio Gebbia, et al. · Journal of Clinical Oncology · 779
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
2016 · Sabine Tejpar, Sebastian Stintzing, et al. · JAMA Oncology · 707
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
2021 · Josep Tabernero, Axel Grothey, et al. · Journal of Clinical Oncology · 567
PDF
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
2009 · E. Van Cutsem, F. Rivera, et al. · Annals of Oncology · 532
A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
2014 · Bengt Gustavsson, Göran Carlsson, et al. · Clinical Colorectal Cancer · 519
PDF
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
2009 · Scott Kopetz, Paulo M. Hoff, et al. · Journal of Clinical Oncology · 485
Irinotecan: 25 years of cancer treatment
2019 · Christian Bailly · Pharmacological Research · 456
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
2014 · Alan P. Venook, Donna Niedzwiecki, et al. · Journal of Clinical Oncology · 428
Works count: 5,455
Citation count: 78,680
Year
Topic
Type